Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Intellia Therapeutics Inc NTLA

Healthcare Biotechnology
Intellia Therapeutics, Inc. is a clinical-stage genome editing company, which is focused on developing curative therapeutics using Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) technology. CRISPR/Cas9 is a technology for genome editing, the process of altering selected sequences of genomic deoxyribonucleic acid. It is focused on leveraging its... see more

Recent & Breaking News (NDAQ:NTLA)

Intellia Therapeutics to Present at September Healthcare Investor Conferences

GlobeNewswire August 27, 2018

Intellia Therapeutics Presents Progress in Lead In Vivo Program at Cold Spring Harbor Laboratory’s Fourth Meeting on Genome Engineering: The CRISPR-Cas Revolution

GlobeNewswire August 23, 2018

Intellia Therapeutics to Host Educational Briefing Webinar on Interference Proceedings Relating to CRISPR/Cas9 Genome Editing Technology Patents

GlobeNewswire August 23, 2018

Intellia Therapeutics Announces Second Quarter 2018 Financial Results

GlobeNewswire August 1, 2018

CRISPR Therapeutics, Intellia Therapeutics and Caribou Biosciences Announce Grant of U.S. Patent for CRISPR/Cas9 Genome Editing

GlobeNewswire June 19, 2018

Intellia Therapeutics Announces WT1 as Its First Cell Therapy Target, Following Presentation of Early Data at the American Society of Gene and Cell Therapy 21st Annual Meeting

GlobeNewswire May 17, 2018

New Scientific Advisors Focused on Cell Therapy in Immuno-Oncology and Autoimmunity Join Intellia Therapeutics

GlobeNewswire May 14, 2018

Intellia Therapeutics Announces First Quarter 2018 Financial Results

GlobeNewswire May 1, 2018

Intellia Therapeutics Announces Fourth Quarter and Full Year 2017 Financial Results

GlobeNewswire March 14, 2018

Intellia Therapeutics to Present at March Healthcare Investor Conferences

GlobeNewswire February 28, 2018

Intellia Therapeutics Announces Publication in Cell Reports of Preclinical Data Demonstrating Effective CRISPR/Cas9 Genome Editing Using Lipid Nanoparticle (LNP) Delivery Technology

GlobeNewswire February 27, 2018

Report: Developing Opportunities within St. Joe, Stone Energy, TravelCenters of America, Intellia Therapeutics, United Community Banks, and Restoration Robotics — Future Expectations, Projections Moving into 2018

GlobeNewswire February 26, 2018

Intellia Therapeutics to Present at February Healthcare Investor Conferences

GlobeNewswire January 31, 2018

Intellia Therapeutics Names John Leonard, M.D., President and Chief Executive Officer

GlobeNewswire December 18, 2017

Intellia Therapeutics Announces New, Robust Genome Editing Data for Sickle Cell Disease at the American Society of Hematology Meeting

GlobeNewswire December 11, 2017

Intellia Therapeutics to Present at November Healthcare Investor Conferences

GlobeNewswire November 2, 2017

Intellia Therapeutics Announces Pricing of Public Offering of Common Stock

GlobeNewswire November 1, 2017

Intellia Therapeutics Announces Proposed Public Offering of Common Stock

GlobeNewswire November 1, 2017

Intellia Therapeutics Announces Third Quarter 2017 Financial Results

GlobeNewswire October 31, 2017

Intellia Therapeutics, Inc. to Host Earnings Call

Accesswire October 31, 2017